U.S.A, novel drugs, and NEW DRUG applications.Have been submitted by pharmaceutical clients who've referenced the DMF held by MPL...this was mentioned in the MD&A and in the CC. Similar info is published on the investors deck found on the corporate website..I would image once rescheduling takes effect FDA approval is more easily attainable as opposed to the current schedule the API falls under... considering this information has been on the investor deck for well over a year the application has been sitting with the FDA for a LONG time....if approved this stock will explode and my view on the holdup has to do with the schedule and once this stance officially changes we could see approval shortly after..for this tight lipped management team to bring up the new drug applications for the first time on CC and MD&A is significant IMO